NRx Pharmaceuticals, Inc.

NasdaqCM NRXP

NRx Pharmaceuticals, Inc. Total Assets for the quarter ending September 30, 2024

NRx Pharmaceuticals, Inc. Total Assets is NA for the quarter ending September 30, 2024. Total assets are the total value of all assets owned by a company, representing its resources.

NRx Pharmaceuticals, Inc. Total Assets for the quarter ending September 30, 2020 was USD 6.03 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqCM: NRXP

NRx Pharmaceuticals, Inc.

CEO	Dr. Jonathan C. Javitt M.D., M.P.H.
IPO Date	Dec. 4, 2017
Location	United States
Headquarters	1201 Orange Street
Employees	2
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Key trends

Past 5 years